Cat. #151335
Anti-CD22 [RFB-4]
Cat. #: 151335
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: CD22
Class: Monoclonal
Application: FACS ; IHC ; IF
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: University College London (UCL)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD22 [RFB-4]
- Research fields: Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Stem cell biology
- Clone: RFB-4
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 153 kDa
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IF
- Description: Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
- Immunogen: Tonsil lymphocytes
- Isotype: IgG1
- Myeloma used: P3X63Ag8
Target Details
- Target: CD22
- Molecular weight: 153 kDa
- Target background: Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
Applications
- Application: FACS ; IHC ; IF
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -80° C
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-CD22, Recombinant [RFB-4]
References
- DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048.
- Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
- Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328.
- Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
- Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.
- Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.
- Human B cell development. II. Subpopulations in the human fetus.
- Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.
